New PET Imaging Agent for Recurrent Prostate Cancer Approved by US FDA
By MedImaging International staff writers Posted on 06 Jun 2016 |
Image: The newly approved PET imaging agent Fluciclovine (18F) anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid (FACBC) is a synthetic amino acid (Photo courtesy of Blue Earth Diagnostics).
The US Food and Drug Administration (FDA) has approved the first PET imaging molecular imaging agent for use in patients who have suspected recurrent prostate cancer.
The agent is indicated for use in Positron Emission Tomography (PET) imaging, is administered by injection, and can help clinicians identify suspected recurrence of prostate cancer in men. The agent is intended for patients with elevated levels of Prostate Specific Antigen (PSA) in their blood following prior treatment. Primary prostate cancer can be treated successfully, but recurrence can occur in nearly 33% of patients, and is detected by testing the PSA levels in the blood.
Blue Earth Diagnostics (BED; Oxford, UK) licensed the agent, Axumin (fluciclovine F 18), from GE Healthcare (Chalfont St Giles, Buckinghamshire, UK), and is investigating the molecule for other potential cancer indications, such as glioma. The FDA-approval follows two successful clinical studies of Axumin.
Brian F. Chapin, MD, assistant professor, Department of Urology, the University of Texas MD Anderson Cancer Center, said, “Approximately 180,000 new cases of prostate cancer are expected to be diagnosed in the United States in 2016, and between 20 to 30 percent of patients receiving primary therapy will develop biochemically recurrent disease. There is a need for clinical imaging techniques that can detect and localize suspected recurrent prostate cancer to facilitate the most appropriate patient management decision. Current commercially available imaging techniques have some limitations in terms of identifying recurrent tumors, which may impact subsequent patient management decisions. Additionally, many patient care options for men with suspected recurrent prostate cancer have uncertain benefits that may not justify the risk of side effects. New imaging procedures that can provide reliable information can be useful tools for effective patient management and care.”
Related Links:
Blue Earth Diagnostics
GE Healthcare
The agent is indicated for use in Positron Emission Tomography (PET) imaging, is administered by injection, and can help clinicians identify suspected recurrence of prostate cancer in men. The agent is intended for patients with elevated levels of Prostate Specific Antigen (PSA) in their blood following prior treatment. Primary prostate cancer can be treated successfully, but recurrence can occur in nearly 33% of patients, and is detected by testing the PSA levels in the blood.
Blue Earth Diagnostics (BED; Oxford, UK) licensed the agent, Axumin (fluciclovine F 18), from GE Healthcare (Chalfont St Giles, Buckinghamshire, UK), and is investigating the molecule for other potential cancer indications, such as glioma. The FDA-approval follows two successful clinical studies of Axumin.
Brian F. Chapin, MD, assistant professor, Department of Urology, the University of Texas MD Anderson Cancer Center, said, “Approximately 180,000 new cases of prostate cancer are expected to be diagnosed in the United States in 2016, and between 20 to 30 percent of patients receiving primary therapy will develop biochemically recurrent disease. There is a need for clinical imaging techniques that can detect and localize suspected recurrent prostate cancer to facilitate the most appropriate patient management decision. Current commercially available imaging techniques have some limitations in terms of identifying recurrent tumors, which may impact subsequent patient management decisions. Additionally, many patient care options for men with suspected recurrent prostate cancer have uncertain benefits that may not justify the risk of side effects. New imaging procedures that can provide reliable information can be useful tools for effective patient management and care.”
Related Links:
Blue Earth Diagnostics
GE Healthcare
Latest Nuclear Medicine News
- New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment